Cost-effectiveness of preimplantation genetic testing for aneuploidy for fresh donor oocyte cycles

• Main Authors: Maria Facadio Antero, M.D (Author), Bhuchitra Singh, M.D., M.P.H, M.S (Author), Apoorva Pradhan, B.A.M.S., M.P.H (Author), Megan Gornet, M.D (Author), William G. Kearns, Ph.D (Author), Valerie Baker, M.D., M.P.P (Author), Mindy S. Christianson, M.D (Author)
• Format: Book
• Published: Elsevier, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Objective: To determine whether in vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) is cost effective to achieve a live birth compared with IVF alone in fresh donor oocyte cycles. Design: Theoretical cost-effectiveness study. Setting: Not applicable. Patient(s): None. Intervention(s): Comparison between the cost of IVF with PGT-A vs. IVF alone to achieve a live birth. The model analyzed a hypothetical single fresh oocyte donor IVF cycle with PGT-A vs. IVF alone and followed the progression of a single embryo through the different decision nodes. Cost estimates assigned to each clinical event were based on data obtained from the literature and institutional costs. Main Outcome Measure(s): Cost per live birth. Result(s): In the base-case analysis, IVF with PGT-A was not cost effective in fresh donor oocyte cycles when compared with IVF alone to achieve a live birth. The cycles using PGT-A cost an additional $6,018.66. The incremental cost-effectiveness ratio was found to be $119,606.59 per additional live birth achieved with IVF with PGT-A. Monte Carlo simulations demonstrated that IVF with PGT-A was not cost effective in nearly all iterations. Conclusion(s): PGT-A in fresh donor oocyte IVF cycles is not cost effective compared with IVF alone over a wide range of probabilities and costs.

Item Description

2666-3341
10.1016/j.xfre.2020.11.005